Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

BACKGROUND: Larotrectinib is a first-in-class, highly selective tropomyosin receptor kinase (TRK) inhibitor approved to treat adult and pediatric patients with TRK fusion-positive cancer. The aim of this study was to evaluate the efficacy and safety of larotrectinib in patients with TRK fusion-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Doz, François, van Tilburg, Cornelis M, Geoerger, Birgit, Højgaard, Martin, Øra, Ingrid, Boni, Valentina, Capra, Michael, Chisholm, Julia, Chung, Hyun Cheol, DuBois, Steven G, Gallego-Melcon, Soledad, Gerber, Nicolas U, Goto, Hiroaki, Grilley-Olson, Juneko E, Hansford, Jordan R, Hong, David S, Italiano, Antoine, Kang, Hyoung Jin, Nysom, Karsten, Thorwarth, Anne, Stefanowicz, Joanna, Tahara, Makoto, Ziegler, David S, Gavrilovic, Igor T, Norenberg, Ricarda, Dima, Laura, De La Cuesta, Esther, Laetsch, Theodore W, Drilon, Alexander, Perreault, Sebastien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Pediatric Neuro-Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159442/
https://www.ncbi.nlm.nih.gov/pubmed/34850167
http://dx.doi.org/10.1093/neuonc/noab274

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9159442/
https://www.ncbi.nlm.nih.gov/pubmed/34850167
http://dx.doi.org/10.1093/neuonc/noab274

Ejemplares similares